Syngene: Strong play on ‘China Switches’ in the CRAMS space
Syngene International Q1 earnings update
Navigating the Shift from China: The Future of Global Pharma Supply Chains
The Importance of Strategic Investments and Technological Advancements
The Blockbuster Biosimilar Drugs
CDMO trends post-Wuxi’s exit from the US: who will take its place?
The Next Frontier Global Leadership on Global Pharma
Insights from Leading Indian CDMOs on the Impact of the BIOSECURE Act and the Shift from Chinese CDMOs
How Indian pharma uses AI to develop faster and cheaper medicines to treat rare diseases
Balancing Innovation with Regulatory Requirements in a CRDMO Setting